Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

作者：Tsai Ya Chu; Tsai Tsen Fang^*

来源：Therapeutic Advances in Musculoskeletal Disease, 2017, 9(11): 277-294.

DOI：10.1177/1759720X17735756

• anti-interleukin therapy
• biologic agents
• interleukin
• psoriasis

Anti-interleukin (IL) therapies have emerged as a major treatment for patients with moderate-to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, IL-20, IL-22, IL-23, IL-36 and bispecific biologics IL-17A/tumor necrosis factor alpha (TNF-alpha). Cytokines involved in the circuits of psoriasis inflammation without ongoing clinical trials are also mentioned (IL-9, IL-13, IL-15, IL-16, IL-18, IL-19, IL-21, IL-24, IL-27, IL-33, IL-35, IL-37, and IL-38).

• 出版日期2017-11